The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

Completed · Phase 1

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes of different race and/or ethnicity.

Key facts

Study ID

NCT01043510

Run by

Novo Nordisk A/S

People needed

63

Starts

2010-01-01

Expected to finish

2010-10-01

Last updated by the study team

2017-01-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Either - Black or African American not of Hispanic or Latino origin or - White of Hispanic or Latino origin or - White not of Hispanic or Latino origin
• Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
• Treated with insulin for at least 3 months, alone or in combination with maximum 2 oral antidiabetic drugs (OADs)
• Body mass index maximum 40.0 kg/m\^2

You may not qualify if…

• Use of GLP-1 receptor agonists (exenatide, liraglutide), thiazolidinediones or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
• History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
• Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening

Where it is running

• Novo Nordisk Investigational Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.